Tatva Chintan Pharma Chem Approves Rs 200 Crore Greenfield Expansion in Gujarat
Tatva Chintan Pharma Chem Limited approves a Rs 200 Crore greenfield expansion at Dahej-III to add 344 KL reactor capacity over 21 months for specialty chemicals.
ALFA News
Straight from the exchange filing
Latest Specialty Chemicals stock news from NSE and BSE filings, 32 stories so far.
Tatva Chintan Pharma Chem Limited approves a Rs 200 Crore greenfield expansion at Dahej-III to add 344 KL reactor capacity over 21 months for specialty chemicals.
Anupam Rasayan signs a $300 Million (₹2,880 Crore) Letter of Intent with Spain's Basquevolt for specialty chemicals over 10 years to boost electronic chemicals.
Aether Industries starts commercial operations at its new Manufacturing Site 5 in Panoli, Gujarat, aiming to drive revenue growth and expand production capacity.
Tinna Rubber & Infrastructure starts commercial operations at its Varale facility with the first dispatch of rCB and TPO, driving 21.64% revenue growth momentum.
Anupam Rasayan India Ltd commercialises ETFA using flow chemistry for a USD 600M global market, marking a world-first achievement for the specialty chemical firm.
Chemplast Sanmar Ltd starts commercial production at Phase III Multi-Purpose Block in Berigai. The specialty chemicals expansion marks a key growth milestone.
Laxmi Organic Industries (LXCHEM) successfully commissions its new Ethyl Acetate plant at the Lote Site in Maharashtra and begins commercial dispatches today.
Platinum Industries starts full commercial production at its Palghar facility as of May 21, 2026, marking a significant expansion in the specialty chemicals sector.
Atul Ltd introduces Mylonis, Salix Gold, and Tikadis to bolster its crop protection portfolio. The chemical major reports TTM revenue of ₹6,273.54 crore.
Vishnu Chemicals resumes full production at its Visakhapatnam Parwada plant after maintenance. The chemical player reports a TTM revenue of ₹1,552.02 crore.
AVI Polymers Ltd launches Ashwini Healthcare AI with 5,620 users. The SaaS platform targets ₹12 Crore ARR, marking a strategic pivot into high-margin healthtech.
Privi Speciality Chemicals Limited receives NSE observation letter with no objection for its merger with two subsidiaries. BSE approval is currently awaited.